Ítem
Acceso Abierto

Preliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model

Mostrar el registro sencillo de la publicación
dc.creatorLambraño, Jenniferspa
dc.creatorCurtidor, Hernandospa
dc.creatorAvendaño, Catalinaspa
dc.creatorDíaz Arévalo, Diana
dc.creatorRoa, Leonardospa
dc.creatorVanegas, Magnoliaspa
dc.creatorPatarroyo, Manuel Espa
dc.creatorPatarroyo, Manuel A.
dc.date.accessioned2020-05-25T23:56:14Z
dc.date.available2020-05-25T23:56:14Z
dc.date.created2019spa
dc.description.abstractMalaria continues being a high-impact disease regarding public health worldwide; the WHO report for malaria in 2018 estimated that 219 million cases occurred in 2017, mostly caused by the parasite Plasmodium falciparum. The disease cost the lives of more than 400,000 people, mainly in Africa. In spite of great efforts aimed at developing better prevention (i.e., a highly effective vaccine), diagnosis, and treatment methods for malaria, no efficient solution to this disease has been advanced to date. The Fundación Instituto de Inmunología de Colombia (FIDIC) has been developing studies aimed at furthering the search for vaccine candidates for controlling P. falciparum malaria. However, vaccine development involves safety and immunogenicity studies regarding their formulation in animal models before proceeding to clinical studies. The present work has thus been aimed at evaluating the safety and immunogenicity of a mixture of 23 chemically synthesised, modified peptides (immune protection-inducing protein structure (IMPIPS)) derived from different P. falciparum proteins. Single and repeat dose assays were thus used with male and female BALB/c mice which were immunised with the IMPIPS mixture. It was found that single and repeat dose immunisation with the IMPIPS mixture was safe, both locally and systemically. It was observed that the antibodies so stimulated recognised the parasite's native proteins and inhibited merozoite invasion of red blood cells in vitro when evaluating the humoral immune response induced by the IMPIPS mixture. Such results suggested that the IMPIPS peptide mixture could be a safe candidate to be tested during the next stage involved in developing an antimalarial vaccine, evaluating local safety, immunogenicity, and protection in a nonhuman primate model. © 2019 Jennifer Lambraño et al.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1155/2019/3832513
dc.identifier.issn23147156
dc.identifier.issn23148861
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22372
dc.language.isoengspa
dc.publisherHindawi Limitedspa
dc.relation.citationTitleJournal of Immunology Research
dc.relation.citationVolumeVol. 2019
dc.relation.ispartofJournal of Immunology Research, ISSN:23147156, 23148861, Vol.2019,(2019)spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85077994868&doi=10.1155%2f2019%2f3832513&partnerID=40&md5=8ee5d79bf42369796bc1c56222f9ec11spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAdjuvantspa
dc.subject.keywordImmune protection inducing protein structure vaccinespa
dc.subject.keywordMalaria vaccinespa
dc.subject.keywordPlasmodium falciparum proteinspa
dc.subject.keywordProtozoal proteinspa
dc.subject.keywordUnclassified drugspa
dc.subject.keywordAnimal cellspa
dc.subject.keywordAnimal experimentspa
dc.subject.keywordArticlespa
dc.subject.keywordControlled studyspa
dc.subject.keywordDrug formulationspa
dc.subject.keywordDrug safetyspa
dc.subject.keywordDrug synthesisspa
dc.subject.keywordErythrocytespa
dc.subject.keywordFemalespa
dc.subject.keywordHumoral immunityspa
dc.subject.keywordImmunizationspa
dc.subject.keywordImmunogenicityspa
dc.subject.keywordImmunological tolerancespa
dc.subject.keywordIn vitro studyspa
dc.subject.keywordIn vivo studyspa
dc.subject.keywordMalaria falciparumspa
dc.subject.keywordMalespa
dc.subject.keywordMerozoitespa
dc.subject.keywordMousespa
dc.subject.keywordNonhumanspa
dc.subject.keywordPlasmodium falciparumspa
dc.subject.keywordProtein structurespa
dc.subject.keywordRepeated drug dosespa
dc.subject.keywordSingle drug dosespa
dc.subject.keywordVaccine immunogenicityspa
dc.titlePreliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Modelspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
3832513.pdf
Tamaño:
3.79 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos